FLEX NEOADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from FLEX
Evidence / Neoadjuvant / FLEX
MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Source: San Antonio Breast Cancer Symposium® Authors: Joyce O’Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigators’ Group Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Read More
Improved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreEBCC 2024: The New Era of Genomic Testing in Early Stage Breast Cancer
EBCC 2024, Oral Presentation Presenter: Dr. Caroline Drukker
Read MoreMammaPrint + BluePrint predict anthracycline chemosensitivity, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 36 Authors: Audeh et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreMammaPrint + BluePrint predict pCR after NCT-FLEX, O’Shaughnessy et al., SABCS 2023 Abstract
SABCS 2023, PO5-15-04 Authors: O'Shaughnessy et al.
Read More
